GlassScriptPhysician profile
Yao Y Yang
NPI 1881702751
$4,939.52
in general payments reported to CMS, 2019-2025
40 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $176 · 2021: $487 · 2022: $780 · 2023: $772 · 2024: $961 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $817.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $758.90 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $447.95 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $431.04 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $367.09 | 2019-2023 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $281.65 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.04 | 2019-2025 | Jardiance, Ofev |
| Grifols USA, LLC | $140.00 | 2024-2025 | Prolastin-C Liquid |
| Amarin Pharma, INC. | $136.36 | 2019-2022 | |
| Astellas Pharma US INC | $107.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $105.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.04 | 2020-2025 | |
| Eisai INC. | $78.67 | 2021-2022 | |
| Abbott Laboratories | $78.45 | 2022-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $75.05 | 2023-2025 | Gemtesa |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$376,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yao Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.